BRAFV600E mutation does not predict lymph node metastases and recurrence in Chinese papillary thyroid microcarcinoma patients
H Zhao, C Liu, Y Lu, SZ Liu, P Yeerkenbieke, Y Cao… - Oral Oncology, 2024 - Elsevier
Object: Previous studies suggest BRAF V600E mutation is a marker for poor prognosis in
papillary thyroid cancer, however, its ability to further risk stratify papillary thyroid …
papillary thyroid cancer, however, its ability to further risk stratify papillary thyroid …
[PDF][PDF] 纳米炭在甲状腺手术中使用方法的全国百名专家10 年经验问卷调查报告
董治中， 饶德伟， 何欣， 杞灵斌， 苏艳军， 郑向前… - 中国普通外科杂志, 2023 - zpwz.net
摘要背景与目的: 纳米炭混悬注射液(以下简称纳米炭) 作为一种淋巴结示踪剂,
已广泛应用于甲状腺手术中快速识别甲状旁腺, 避免手术误伤. 然而, 目前甲状腺乳头状癌(PTC) …
已广泛应用于甲状腺手术中快速识别甲状旁腺, 避免手术误伤. 然而, 目前甲状腺乳头状癌(PTC) …
Predicting central cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis: a practical nomogram based on retrospective study
L Wang, L Zhang, D Wang, J Chen, W Su, L Sun… - PeerJ, 2024 - peerj.com
Background In papillary thyroid carcinoma (PTC) patients with Hashimoto's thyroiditis (HT),
preoperative ultrasonography frequently reveals the presence of enlarged lymph nodes in …
preoperative ultrasonography frequently reveals the presence of enlarged lymph nodes in …
[HTML][HTML] Interpretable machine learning model based on the systemic inflammation response index and ultrasound features can predict central lymph node metastasis …
J Pang, M Yang, J Li, X Zhong, X Shen, T Chen… - Gland …, 2023 - ncbi.nlm.nih.gov
Background It is arguable whether individuals with T1–T2 papillary thyroid cancer (PTC)
who have a clinically negative (cN0) diagnosis should undergo prophylactic central lymph …
who have a clinically negative (cN0) diagnosis should undergo prophylactic central lymph …